Results 101 to 110 of about 1,879,895 (298)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

On the number of Smarandache zero-divisors and Smarandache weak zero-divisors in loop rings [PDF]

open access: yes, 2005
Finding the number of Smarandache zero divisors (S-zero divisors) and Smarandache weak zero divisors (S-weak zero divisors) for the loop ...
Chetry, K. Moon, Vasantha, W.B.
core   +1 more source

An amphiphilic pseudo[1]catenane: neutral guest-induced clouding point change

open access: yesBeilstein Journal of Organic Chemistry, 2018
The hydrophobic/hydrophilic ratio in a molecule largely affects its assembled properties in aqueous media. In this study, we synthesized a new bicyclic compound which could dynamically change its hydrophobic/hydrophilic ratio by chemical stimulus.
Tomoki Ogoshi   +2 more
doaj   +1 more source

Crystal structure of 4,6-bis[(E)-4-bromostyryl]-2-(butylsulfanyl)pyrimidine

open access: yesActa Crystallographica Section E, 2014
In the title compound, C24H22Br2N2S, the dihedral angles between the central pyrimidine ring and the pendant bromobenzene rings are 11.02 (11) and 13.20 (12)°. The butyl side chain adopts a gauche conformation [C—C—C—C = −67.4 (4)°]. In the crystal, weak
Wang Yu, Jingbao Song, Aijian Wang
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

On Regular Rings Satisfying Weak Chain Condition [PDF]

open access: yes, 2006
In this paper, we shall study regular rings satisfying weak chain condition. As main results, we show that regular rings satisfying weak chain condition are unit-regular, and show that these rings have the unperforation and power cancellation properties ...
Kutami, Mamoru
core   +1 more source

MDS and MHDR Cyclic Codes over Finite Chain Rings

open access: yesJournal of Mathematics
This work establishes a unique set of generators for a cyclic code over a finite chain ring. Towards this, we first determine the minimal spanning set and rank of the code.
Monika Dalal   +2 more
doaj   +1 more source

Crystal structure of 2′-[(2′,4′-difluorobiphenyl-4-yl)carbonyl]-1′-phenyl-1′,2′,5′,6′,7′,7a'-hexahydrospiro[indole-3,3′-pyrrolizin]-2(1H)-one

open access: yesActa Crystallographica Section E: Crystallographic Communications, 2015
In the title pyrrolizidine derivative, C33H26F2N2O2, both pyrrolidine rings of the pyrrolizidine moiety adopt an envelope conformation. The difluorophenyl group is oriented at an angle of 54.3 (1)° with respect to the oxindole moiety. The crystal packing
M. Fathimunnisa   +3 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy